We are live on ! Find out more

715 hedge funds and large institutions have $8.08B invested in Sanofi in 2026 Q2 according to their latest regulatory filings, with 89 funds opening new positions, 211 increasing their positions, 295 reducing their positions, and 101 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.86% less ownership

Funds ownership: 8.66%7.81% (-0.86%)

4% less funds holding

Funds holding: 745715 (-30)

12% less first-time investments, than exits

New positions opened: 89 | Existing positions closed: 101

16% less call options, than puts

Call options by funds: $116M | Put options by funds: $138M

20% less capital invested

Capital invested by funds: $10.1B → $8.08B (-$2.01B)

28% less repeat investments, than reductions

Existing positions increased: 211 | Existing positions reduced: 295

50% less funds holding in top 10

Funds holding in top 10: 63 (-3)

Holders
715
Holders Change
-30
Holders Change %
-4.03%
% of All Funds
8.6%
Holding in Top 10
3
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
89
Increased
211
Reduced
295
Closed
101
Calls
$116M
Puts
$138M
Net Calls
-$21.9M
Net Calls Change
-$3.58M

SNY Hedge Fund Activity: Q2 2026 in Review

715 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q2 2026, worth a combined $8.08B — down 20% from $10.1B a quarter earlier.

Sellers outnumbered buyers: 101 funds closed out of SNY and 89 opened new positions — a net loss of 12 holders — while 295 trimmed existing stakes and 211 added.

The largest buyer was Balyasny Asset Management, adding an estimated $70.2M. The largest seller was Franklin Resources, cutting an estimated $312M.

  • 715 institutional investors held Sanofi (SNY) as of Q2 2026, down from 745 in Q1 2026.
  • Funds reported $8.08B of Sanofi stock for Q2 2026, down 20% quarter-over-quarter.
  • 89 funds opened new Sanofi positions in Q2 2026 and 101 closed out, a net change of -12 holders.
  • The largest Sanofi buyer in Q2 2026 was Balyasny Asset Management, an estimated $70.2M added.
  • The largest Sanofi seller in Q2 2026 was Franklin Resources, an estimated $312M sold.

Based on aggregated 13F filings for Q2 2026.